Skip to main content

Nivolumab and total neoadjuvant treatment for locally advanced rectal cancer: results of a phase II trial (CA209-8M4)

In brief

Nivolumab-based rectal cancer treatment had a 68% composite complete-response rate

In this 29-patient phase II trial, 68% of assessable patients either had no cancer found at surgery or maintained a clinical complete response for at least 12 months without surgery. More than half had severe side effects during treatment, and the single-arm results cannot show whether nivolumab improved outcomes; a randomized trial is ongoing.

Journal
ESMO open (Q1)
Published
11 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
B Brenner, G Perl, A Rosenberg-Ayal, M Cohavi, A Sulkes, Z Cohen, et al.
PMID
43014085
DOI
10.1016/j.esmoop.2026.108617

Why clinicians should know about it

  • Picked for Surgical Oncology (top studies of the week, 15 November 2026): Nivolumab added to TNT, neoadjuvant response

Abstract

BACKGROUND: CA209-8M4 is a prospective phase II trial evaluating the addition of nivolumab to total neoadjuvant treatment (TNT) in patients with locally advanced rectal cancer (LARC). MATERIALS AND METHODS: Patients with LARC (T3-4Nany or TanyN1) up to 12 cm from the anal verge received standard chemoradiation (CRT) followed by chemoimmunotherapy (CIMT): six cycles of standard mFOLFOX6 and nivolumab at 240 mg. We defined a novel primary endpoint, combining pathological complete response (pCR) rate among operated patients and long-term (≥12 months) clinical complete response (cCR) rate for those electing watchful waiting, into a composite endpoint of modified pCR (mpCR) rate. RESULTS: Between April 2019 and March 2024, 29 patients were enrolled, median age 53 years, 72.4% male; 96.6% of tumors were cT3 or cT4, 69.0% cN+, and 96.6% microsatellite stable. Median distance from the anal verge was 7 cm; 51.7% of patients had grade ≥3 adverse events (AEs) during CIMT, including one fatality (mesenteric inflammation), attributed most likely to CRT's unresolved toxicity. Immune-mediated AEs occurred in four patients (13.8%): grade 3 diabetes mellitus (1) and grade 1 hepatitis (3), including one with asymptomatic hyper/hypothyroidism. Twenty-eight patients (96.6%) are assessable for mpCR: 6 of the 15 operated achieved pCR, and 13 were not operated with cCR ≥12 months, leading to a 67.9% mpCR rate. With a median follow-up of 43.5 months (range 25.0-84.1+), all 28 assessable pts are alive with no evidence of disease. The estimated 3-year disease-free survival and 5-year overall survival rates of the entire group are 93% [95% confidence interval (CI) 84-100] and 97% (95% CI 90-100), respectively. CONCLUSIONS: The addition of nivolumab to standard TNT in LARC seems safe and may enhance its effectiveness, with encouraging mpCR and survival rates. A multicenter randomized trial, further evaluating this strategy, is ongoing.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.